Partner 1

Discovery of bicyclic thymidine analogues as selective and high affinity inhibitors of mycobacterium Tuberculosis thymidine monophosphate kinase.
V. Vanheusden, H. Munier-Lehmann, M. Froeyen, J. Rozenski, P. Herdewijn, S. Van Calenbergh. J. Med. Chem. 2004, 47, 6187-6194.

Deoxythreosyl phosphonate nucleosides as selective anti-HIV agents.
T. Wu, M. Froeyen, V. Kempeneers, C. Pannecouque, J. Wang, R. Busson, E. De Clercq, P. Herdewijn. J. Am. Chem. Soc. 2005, 127, 5056-5065.

Enzymatic and structural analysis of inhibitors designed against M. tuberculosis thymidylate kinase: new insights into the phosphoryl transfer mechanism.
A. Haouz, V. Vanheusden, M. Munier-Lehmann, M. Froeyen, P. Herdewijn, S. Van Calenbergh, M. Delarue. J. Biol. Chem. 2003, 278, 4963-4971.

Inhibition of MDR1 expression with altritol modified siRNA.
M. Fisher, M. Abramov, A. Van Aerschot, D. Xu, R. Juliano, P. Herdewijn. Nucleic Acids Res. 2007, 35, 1064-1074.

Computational alanine scanning and free energy decomposition for E. coli type 1 signal peptidase with lipopeptide inhibitor complex.
T. Li, M. Froeyen, P. Herdewijn J. Mol. Graph. Model. 2008, 26, 813-823.

Title: New Approaches to Target Tuberculosis

Acronym: NATT

Contract number: 222965

EC contribution: 2.994.478 €

Duration: 36 months

Starting date: 01/10/2008

Collaborative project